Ectoparasites (eBook)
376 Seiten
Wiley-VCH Verlag GmbH & Co. KGaA
978-3-527-80289-0 (ISBN)
Edited by a team combining 80 years of experience in academic research and industrial antiparasitic drug discovery, this volume of Drug Discovery in Infectious Diseases summarizes current knowledge in this rapidly expanding field. Comprehensive yet concise, this ready reference blends solid background information on ectoparasite biology with the very latest methods in ectoparasite drug discovery. Three major parts cover current ectoparasite control strategies and the threat of drug resistance, screening and drug evaluation, and the new isoxazoline class of ectoparasiticides. The future potential of mechanism-based approaches for repellents and parasiticides is thoroughly discussed, as are strategies for vaccines against ectoparasites, making the book ideal for parasitologists in academia as well as researchers working in the pharmaceutical industry. Dieses einzigartige Referenzwerk deckt die Biologie von Parasiten, heutige Arzneimittel, die neuesten Werkzeuge der Wirkstoffforschung, molekulare Targets sowie neuartige Therapeutika ab und ist ideal für alle Experten der Ektoparasitologie in der Veterinärmedizin und Medizin.
Dr. Charles Q. Meng earned his PhD degree in Organic Chemistry from the University of Zurich in 1991. Upon completing postdoctoral research at Roche (Basel) and the University of Montreal he worked for Allelix Biopharmaceuticals (Mississauga, Ontario) on migraine drug discovery and AtheroGenics (Alpharetta, Georgia) on cardiovascular drug discovery. In 2007 Dr. Meng joined the pharmaceutical discovery and research group of Merial, a Sanofi company then and part of Boehringer Ingelheim now, focusing on antiparasitic drug discovery for animal health. He is an inventor of 25 issued US patents and an author of over 30 publications of original research, reviews, commentaries and book chapters. Dr. Ann E. Sluder earned a PhD in Biochemistry from Duke University in 1988 studying transcription biochemistry in Drosophila melanogaster. During postdoctoral studies at Harvard Medical School and Massachusetts General Hospital she initiated a research program focused on nuclear receptor transcription factors in the nematode Caenorhabditis elegans, which she expanded to include parasitic nematodes while an Assistant Professor of Cellular Biology at the University of Georgia. From 2000-2014 Dr. Sluder worked in drug discovery for antiparasitics, orphan neuromuscular diseases and viral and fungal infections at two biotechnology companies. In 2015 she joined the Vaccine and Immunotherapy Center of the Massachusetts General Hospital, managing preclinical development programs in infectious diseases, cancer, and diabetes. Prof. Dr. Paul M. Selzer studied Biology, Parasitology, and Biochemistry at the University of Tübingen, Germany, where he also received his PhD in Biochemistry. He spent three years at the Molecular Design Institute and the Tropical Disease Research Laboratory at the University of California, San Francisco. During his career he has worked as a researcher and scientific manager for several pharmaceutical companies, and is currently holding a management position in antiparasitic drug discovery at Boehringer Ingelheim Animal Health. He is also a visiting professor at the Interfaculty Institute of Biochemistry of the University of Tübingen, DE and an honorary professor of the Department of Infection, Immunity, and Inflammation at the University of Glasgow, UK.
PART ONE: Strategies & Resistance
Comparison of Anti-Ectoparasite and Anti-Endoparasite Therapies and Control Strategies
Vaccination Against Ticks
Blocking Transmission in Vector-borne Diseases
The Threat and Reality of Drug Resistance in Cattle Tick Rhipicephalus (Boophilus) microplus
Monitoring Drug Sensitivity in Cattle Ticks
New Developments in the Control of Human Lice
PART TWO: Screens & Models
Molecular Targets to Impair Blood Meal Processing in Ticks
Whole-organism Screens for Ectoparasites
In vitro Feeding Methods for Hematophagus Arthropods and Their Application in Drug Discovery
Testing in Laboratory Animal Models for Ectoparasiticide Discovery and Development
Testing in Target Hosts for Ectoparasiticide Discovery and Development
PART THREE: Isoxazolines
Isoxazolines: A Novel Chemotype Highly Effective on Ectoparasites
The Discovery of Afoxolaner: A New Ectoparasiticide for Dogs
Development of Afoxolaner as a New Ectoparasiticide for Dogs
Discovery, Development, and Commercialization of Sarolaner (Simparica®), A Novel Oral Isoxazoline Ectoparasiticide for Dogs
Isoxazolines: Preeminent Ectoparasiticides of the Early Twenty-first Century
Erscheint lt. Verlag | 1.6.2018 |
---|---|
Reihe/Serie | Drug Discovery in Infectious Diseases |
Mitarbeit |
Herausgeber (Serie): Paul M. Selzer |
Sprache | englisch |
Themenwelt | Naturwissenschaften ► Biologie |
Schlagworte | Biowissenschaften • Chemie • Chemistry • Life Sciences • Parasitologie • Parasitology • Pharmaceutical & Medicinal Chemistry • Pharmazeutische u. Medizinische Chemie • Veterinärmedizin • Veterinärmedizin / Dermatologie • Veterinary Dermatology • Veterinary Medicine |
ISBN-10 | 3-527-80289-4 / 3527802894 |
ISBN-13 | 978-3-527-80289-0 / 9783527802890 |
Haben Sie eine Frage zum Produkt? |
Größe: 7,6 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belletristik und Sachbüchern. Der Fließtext wird dynamisch an die Display- und Schriftgröße angepasst. Auch für mobile Lesegeräte ist EPUB daher gut geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich